Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations

被引:41
作者
Abeliovich, Asa [1 ]
Hefti, Franz [1 ]
Sevigny, Jeffrey [1 ]
机构
[1] Prevail Therapeut, 430 East 29th St, New York, NY 10016 USA
关键词
Gene therapy; GBA1; glucocerebrosidase; Gaucher; AAV9; NEURONOPATHIC GAUCHER-DISEASE; ALPHA-SYNUCLEIN PATHOLOGY; GLUCOCEREBROSIDASE MUTATIONS; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; EXPRESSION; MODELS; MULTICENTER; DELIVERY; RISK;
D O I
10.3233/JPD-212739
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Human genetic studies as well as studies in animal models indicate that lysosomal dysfunction plays a key role in the pathogenesis of Parkinson's disease. Among the lysosomal genes involved, GBA1 has the largest impact on Parkinson's disease risk. Deficiency in the GBA1 encoded enzyme glucocerebrosidase (GCase) leads to the accumulation of the GCase glycolipid substrates glucosylceramide and glucosylsphingosine and ultimately results in toxicity and inflammation and negatively affect many clinical aspects of Parkinson's disease, including disease risk, the severity of presentation, age of onset, and likelihood of progression to dementia. These findings support the view that re-establishing normal levels of GCase enzyme activity may reduce the progression of Parkinson's disease in patients carrying GBA1 mutations. Studies in mouse models indicate that PR001, a AAV9 vector-based gene therapy designed to deliver a functional GBA1 gene to the brain, suggest that this therapeutic approach may slow or stop disease progression. PR001 is currently being evaluated in clinical trials with Parkinson's disease patients carrying GBA1 mutations.
引用
收藏
页码:S183 / S188
页数:6
相关论文
共 59 条
  • [1] Defects in trafficking bridge Parkinson's disease pathology and genetics
    Abeliovich, Asa
    Gitler, Aaron D.
    [J]. NATURE, 2016, 539 (7628) : 207 - 216
  • [2] Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study
    Alcalay, R. N.
    Caccappolo, E.
    Mejia-Santana, H.
    Tang, M. -X.
    Rosado, L.
    Reilly, M. Orbe
    Ruiz, D.
    Ross, B.
    Verbitsky, M.
    Kisselev, S.
    Louis, E.
    Comella, C.
    Colcher, A.
    Jennings, D.
    Nance, M.
    Bressman, S.
    Scott, W. K.
    Tanner, C.
    Mickel, S.
    Andrews, H.
    Waters, C.
    Fahn, S.
    Cote, L.
    Frucht, S.
    Ford, B.
    Rezak, M.
    Novak, K.
    Friedman, J. H.
    Pfeiffer, R.
    Marsh, L.
    Hiner, B.
    Siderowf, A.
    Payami, H.
    Molho, E.
    Factor, S.
    Ottman, R.
    Clark, L. N.
    Marder, K.
    [J]. NEUROLOGY, 2012, 78 (18) : 1434 - 1440
  • [3] Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations
    Alcalay, Roy N.
    Levy, Oren A.
    Waters, Cheryl C.
    Fahn, Stanley
    Ford, Blair
    Kuo, Sheng-Han
    Mazzoni, Pietro
    Pauciulo, Michael W.
    Nichols, William C.
    Gan-Or, Ziv
    Rouleau, Guy A.
    Chung, Wendy K.
    Wolf, Pavlina
    Oliva, Petra
    Keutzer, Joan
    Marder, Karen
    Zhang, Xiaokui
    [J]. BRAIN, 2015, 138 : 2648 - 2658
  • [4] Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
    Alcalay, Roy N.
    Dinur, Tama
    Quinn, Timothy
    Sakanaka, Karina
    Levy, Oren
    Waters, Cheryl
    Fahn, Stanley
    Dorovski, Tsvyatko
    Chung, Wendy K.
    Pauciulo, Michael
    Nichols, William
    Rana, Huma Q.
    Balwani, Manisha
    Bier, Louise
    Elstein, Deborah
    Zimran, Ari
    [J]. JAMA NEUROLOGY, 2014, 71 (06) : 752 - 757
  • [5] Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
    Anheim, M.
    Elbaz, A.
    Lesage, S.
    Durr, A.
    Condroyer, C.
    Viallet, F.
    Pollak, P.
    Bonaiti, B.
    Bonaiti-Pellie, C.
    Brice, A.
    [J]. NEUROLOGY, 2012, 78 (06) : 417 - 420
  • [6] Trio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations
    Arkadir, David
    Dinur, Tama
    Mullin, Stephen
    Mehta, Atul
    Baris, Hagit N.
    Alcalay, Roy N.
    Zimran, Ari
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 115 - 116
  • [7] Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
    Challis, Collin
    Hori, Acacia
    Sampson, Timothy R.
    Yoo, Bryan B.
    Challis, Rosemary C.
    Hamilton, Adam M.
    Mazmanian, Sarkis K.
    Volpicelli-Daley, Laura A.
    Gradinaru, Viviana
    [J]. NATURE NEUROSCIENCE, 2020, 23 (03) : 327 - +
  • [8] Glucocerebrosidase and its relevance to Parkinson disease
    Do, Jenny
    McKinney, Cindy
    Sharma, Pankaj
    Sidransky, Ellen
    [J]. MOLECULAR NEURODEGENERATION, 2019, 14 (01)
  • [9] Animal models for Gaucher disease research
    Farfel-Becker, Tamar
    Vitner, Einat B.
    Futerman, Anthony H.
    [J]. DISEASE MODELS & MECHANISMS, 2011, 4 (06) : 746 - 752
  • [10] Differential effects of severe vs mild GBA mutations on Parkinson disease
    Gan-Or, Ziv
    Amshalom, Idan
    Kilarski, Laura L.
    Bar-Shira, Anat
    Gana-Weisz, Mali
    Mirelman, Anat
    Marder, Karen
    Bressman, Susan
    Giladi, Nir
    Orr-Urtreger, Avi
    [J]. NEUROLOGY, 2015, 84 (09) : 880 - 887